目的:观察肿瘤化疗患者血浆P-选择素及组织因子(TF)变化,活血化瘀代表药物川芎嗪对其的影响,以及与化疗疗效之间的关系,揭示活血化瘀法对化疗增效的机理。方法:观察肿瘤患者与健康志愿者血浆P-选择素及TF差异;通过对实际纳入观察的172例肿瘤化疗患者进行分组对照研究,治疗组为化疗同步应用川芎嗪,对照组为单纯化疗,对比患者血浆P-选择素及TF差异及疗效。结果:治疗组血浆P-选择素及TF较对照组改善明显,疗效更高。结论:活血化瘀药物与化疗同步应用能明显降低血浆P-选择素及TF水平,改善肿瘤患者高凝状态,提高化疗疗效。 OBJECTIVE: To observe the changes of plasma P-selectin and tissue factor (TF) in patients with tumor chemotherapy, the effect of Ligustrazine on it and its relationship with the curative effect of chemotherapy, and to reveal the synergistic effect of chemotherapy for promoting blood circulation and removing blood stasis mechanism. Methods: The plasma P-selectin and TF in tumor patients and healthy volunteers were observed. Through the group-controlled study of 172 patients with chemotherapy and chemotherapy, the patients in the treatment group were treated with ligustrazine simultaneously with chemotherapy and the control group with chemotherapy alone. P-selectin in patients with plasma and TF differences and efficacy. Results: Plasma P-selectin and TF in the treatment group improved significantly compared with the control group, with a higher therapeutic effect. Conclusion: The concurrent application of drugs for activating blood circulation and removing stasis can obviously decrease the plasma P-selectin and TF levels, improve the hypercoagulability state of tumor patients and improve the curative effect of chemotherapy.